Dexamethasone versus methylprednisolone for critical asthma: A single center, open‐label, parallel‐group clinical trial
Authors:
Open Access
- 17 March 2023
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 58 (6) , 1719-1727
Abstract
Background: Evidence for the use of dexamethasone for pediatric critical asthma is limited. We sought to compare the clinical efficacy and safety of dexamethasone versus methylprednisolone among children hospitalized in the pediatric intensive care unit (PICU) for critical asthma.Methods: A prospective, single center, open‐label, two‐arm, parallel‐group, nonrandomized trial among children ages 5−17 years hospitalized within the PICU from April 2019 to December 2021 for critical asthma consented to receive methylprednisolone (standard care) or dexamethasone (intervention) at a 2:1 allocation ratio, respectively. The intervention arm received intravenous dexamethasone 0.25 mg/kg/dose (max: 15 mg/dose) every 6 h for 48 h and the standard care arm intravenous methylprednisolone 1 mg/kg/dose every 6 h (max dose: 60 mg/dose) for 5 days. Study endpoints were clinical efficacy (i.e., length of stay [LOS], continuous albuterol duration, and a composite of adjunctive asthma interventions) and safety (i.e., corticosteroid‐related adverse events).Results: Ninety‐two participants were analyzed of whom 31 were allocated to the intervention arm and 61 the standard care arm. No differences in demographics, clinical characteristics, or acute/chronic asthma severity indices were observed. Regarding efficacy and safety endpoints, no differences in hospital LOS, continuous albuterol duration, adjunctive asthma intervention rates, or corticosteroid‐related adverse events were noted. Compared to the intervention arm, participants in the standard care arm more frequently were prescribed corticosteroids at discharge (72% vs. 13%, p < 0.001).Conclusions: Among children hospitalized for critical asthma, dexamethasone appears safe and warrants further investigation to fully assess clinical efficacy and potential advantages over commonly applied agents such as methylprednisolone.Keywords
This publication has 34 references indexed in Scilit:
- Status of Childhood Asthma in the United States, 1980–2007Pediatrics, 2009
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old DrugsNew England Journal of Medicine, 2005
- Pharmacokinetics and Pharmacodynamics of Systemically Administered GlucocorticoidsClinical Pharmacokinetics, 2005
- Nongenomic Actions of Glucocorticosteroids on the Airway Vasculature in AsthmaProceedings of the American Thoracic Society, 2004
- Performance of a Novel Clinical Score, the Pediatric Asthma Severity Score (PASS), in the Evaluation of Acute AsthmaAcademic Emergency Medicine, 2004
- Improved outcomes for hospitalized asthmatic children using a clinical pathwayAnnals of Allergy, Asthma & Immunology, 2000
- Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of CorticosteroidsThe Journal of Clinical Pharmacology, 1993
- Methylprednisolone pulse therapy in severe acute asthmaAllergy, 1987
- The effect of cortisone on bronchial asthma and hay fever occurring in subjects sensitive to ragweed pollenJournal of Allergy, 1950